Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Noile-Immune Biotech's Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円-372.98 Mil. Therefore, Noile-Immune Biotech's EV-to-EBIT ratio for today is -4.82.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Noile-Immune Biotech's Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円-372.98 Mil. Therefore, Noile-Immune Biotech's EV-to-EBITDA ratio for today is -4.82.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Noile-Immune Biotech (TSE:4893) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-372.98 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-372.98 Mil.
Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2.14 Mil.
Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil.
Noile-Immune Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech Enterprise Value Related Terms
Noile-Immune Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Noile-Immune Biotech's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of 円1,799.07 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Enterprise Value of 円1,799.07 Mil as of Jul. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Enterprise Value too high?
Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Enterprise Value compare to VRTX and REGN?
Noile-Immune Biotech's Enterprise Value of 円1,799.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Enterprise Value is 円1,799.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円128.00 — trading 2835.8% above its estimated fair value. The current Enterprise Value is 円1,799.07 Mil. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Enterprise Value is 円1,799.07 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円128.00 is trading 2835.8% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Enterprise Value: 円1,799.07 Mil
GF Value™: 円4.36 vs. price of 円128.00 (2835.8% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
